

## PROVINCIAL FUNDING SUMMARY

Ofatumumab (Arzerra) for Chronic Lymphocytic Leukemia

pERC Recommendation: Does not recommend  
For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: February 23, 2015

This information is current as of March 29, 2016.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Not Funded		
AB	Under provincial consideration*		
SK	Not Funded		
MB	Not Funded		
ON	Not Funded		
NS	Not Funded		
NB	Not Funded		
NL	Under provincial consideration*		
PEI	Not Funded		

\*Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.